Why the Next Big Hope for Alzheimer’s Might Not Help Most Black Patients
Racial disparities in drug trials, and disparities in overall medical care, among other factors, make the recently-approved Alzheimer's break-through drug lecanemab less likely to benefit African Americans.
https://kffhealthnews.org/news/article/fda-alzheimers-drug-approval-process-lecanemab-leqembi-racial-disparities/Open linkView original on lemm.ee
Update: same holds true for Latinos.
https://www.beingpatient.com/maria-aranda-clinical-trials-latino-alzheimers/